Lifestyle
Tesla lends its automation expertise in search for COVID-19 vaccine
Tesla CEO Elon Musk may have strong disagreements over the political handling of the COVID-19 pandemic, but his actions to help solve the matter strike a more positive note, namely one of progress in vaccine technology.
In a recent Twitter discussion about the uptick in national cases, Musk offered his thoughts on using RNA for immunization therapies.
“In principle, I think synthetic RNA (and DNA) has amazing potential,” he replied. “This basically makes the solution to many diseases a software problem.” Musk then brought attention to the current work Tesla is doing via Tesla Grohmann Automation GmbH in Germany. “Tesla, as a side project, is building RNA microfactories for CureVac & possibly others.”
CureVac AG is a German biotechnology company founded in 2000 with the primary goal of using proteins created with stabilized messenger RNA (mRNA) in disease therapeutics. As described on their official website, the company has “…develop[ed] an extensive in-house nucleotide sequence library that allows us to optimally assemble the various pieces of the mRNA puzzle for the desired therapeutic use…Each CureVac product can be thought of as a tailored molecular creation.” The protein-centric nature of these products may enable the development of a wide variety of therapies, including cancer immunotherapy, antibody production, treatments for rare diseases, and prophylactic vaccines.
In principle, I think synthetic RNA (and DNA) has amazing potential. This basically makes the solution to many diseases a software problem.
— Elon Musk (@elonmusk) July 2, 2020
CureVac’s vaccines use a dose of synthetic mRNA coded for disease-specific proteins or antigens which induce the immune system to respond and produce antibodies. Musk’s comment about diseases being a software problem seems to refer in part to this type of technology. The production side of this specialized mRNA looks to be where their relationship with Tesla is formalized. Specifically, the two companies have developed a bioreactor (referred to by Musk as an ‘RNA microfactory’) which combines Tesla Grohmann’s automation technology with CureVac’s tailored mRNA coding and printing.
A press release by CureVac from February 2019 refers to the bioreactor as The RNA Printer™ describing it as “…a transportable, down-scaled, automated messenger RNA (mRNA) printing facility…that can target known pathogens (including Lassa Fever, Yellow Fever, and Rabies) and prepare for rapid response to new and previously unknown pathogens (referred to by WHO as “Disease X”).” Several partnerships and grants have been accumulated by CureVac to further its development of the machine’s capabilities, and the race for a COVID-19 vaccine has brought even more attention and support to the technology.
Although this pandemic has now provided a spotlight on the Tesla and CureVac partnership, a joint patent application for the bioprinter was originally filed in 2018. Published in January this year, the invention is descriptively titled “Bioreactor for RNA in vitro Transcription” and assigned International Patent Publication No. WO-2020/002598. The Background section of the application provides a bit more insight to the technology, its potential, and why Tesla-style automation really makes a difference in what’s possible:
“A critical step in RNA production is the generation of a suitable DNA template, which at industrial scale is a major cost factor…Manufacturing of RNA requires a large degree of manual handling in a GMP-regulated laboratory executed by well-trained technical staff. In consequence, current established manufacturing processes are time consuming, cost intensive, and require a lot of laboratory space and laboratory equipment.”

Essentially, automating much of the manufacturing process would improve speed and reduce errors from human interaction, just as is the case with Tesla’s automated car manufacturing. Unlike automotive large-scale productions, however, this bioprinter would be much smaller. With staffing needs reduced and the equipment needs reduced to a single machine, portability comes into play.
“…an acceleration of RNA manufacturing would be highly advantageous and of major importance for public health, especially in the context of pandemic scenarios. Further advantageous in that context would be the production of the RNA therapeutics in the region of the outbreak which would, however, require a portable RNA production apparatus.”
It’s not clear exactly which parts of the invention were specifically Tesla’s contribution aside from Musk’s indication that his company would be manufacturing the machines.
Overall, as stated in CureVac’s press release, The RNA Printer™ will be capable of producing enough customized mRNA for 100,000+ vaccine doses within a few weeks and on-site of the outbreak location. The same machine would be flexible enough to be used for a wide variety of pathogens. Notably, CureVac was recently cleared for phase I human trials of its mRNA vaccine for COVID-19.
Musk’s interest in biotechnology is well known to those who follow his many projects and businesses, especially in terms of artificial intelligence as it relates to human-computer interfaces via Neuralink. However, this more traditional philanthropic involvement is surely quite welcome in a world turned upside down by a pandemic.
Elon Musk
Elon Musk says he knows how to save Earth for a billion years
Elon Musk says sentient AI satellites launched from the Moon could keep Earth livable forever.
Elon Musk spent part of his weekend describing a plan to keep the planet livable for roughly a billion years, and it starts with satellites that can think for themselves.
In a post on X, Musk argued that swapping fossil fuels for solar and wind power will not be enough to protect humanity from what he called extremely severe extinction events, the kind that occur roughly every 100 million years. His fix is what he called sentient satellites, or solar-powered satellites, controlled by AI, that would sit in a fixed spot between Earth and the Sun after being launched off the Moon using a giant electromagnetic catapult instead of rockets.
The satellites’ onboard AI would make continuous, small adjustments rather than waiting on human instructions. The mass driver is Musk’s proposed way of getting the raw material there cheaply by using an electromagnetic launch track built on the Moon, where lower gravity and no atmosphere make it far easier to fling cargo into space than it is from Earth.
But we do need to act much faster than that if people still want to live where the beach is today. We have about 50 years or so to take action, which should be more than enough time for the space satellites to solve any heating problems. https://t.co/xhrVQALwQw
— Elon Musk (@elonmusk) August 30, 2026
Musk shared a Grok generated estimate suggesting roughly 5 percent of Florida’s land, or about 1.68 million acres, could face regular flooding by 2070 under a high sea level rise scenario, and said humanity has about 50 years to act before coastal living looks very different than it does today.
This is not the first time Musk has floated the idea. He raised a similar concept in November, describing a solar powered AI satellite constellation that could make tiny adjustments to incoming sunlight to fine tune Earth’s temperature. Musk has also tied planetary risk to his broader vision at SpaceX, where his compensation package is explicitly linked to establishing a self-sustaining Mars colony, one he has described as an insurance policy against the kind of extinction event he referenced this weekend, and where he has said humans could set foot within five to seven years.
Lifestyle
Police sergeant recounts his Neuralink journey with Elon Musk’s brain chip
A former Vancouver police sergeant with ALS accounts his journey to become a patient for Elon Musk’s Neuralink wireless brain-computer interface technology.
“I’m texting you from my brain right now.” That was the first message Lee Marten sent after waking up from Neuralink surgery, five hours and one migraine after dozens of threads were stitched into his motor cortex.
Marten, a former Vancouver police sergeant, is one of the first Canadian ALS patients to receive Neuralink’s N1 brain implant, and the 26th recipient overall. He tells his story in a first-person account published by Maclean’s.
Marten recounts how he was a healthy, athletic Vancouver police sergeant until April 2022 when symptoms of muscle twitching and balance loss, were followed by a bad fall that broke his leg. He would eventually be diagnosed with ALS in early 2025 at the age of 47. ALS, also known as Lou Gehrig’s disease, is a fatal neurodegenerative disease that progressively destroys the motor neurons controlling voluntary muscle movement, eventually taking away a patient’s ability to walk, speak, swallow and breathe. There’s no cure, and most patients live two to five years after diagnosis.
He describes the devastation of the diagnosis and how he began preparing for it while connecting with other young ALS patients through a WhatsApp group called Young Guns. Through that group he learned about a Neuralink clinical trial at Toronto Western Hospital and, after a roughly seven-month vetting process (physical assessments, psychiatric evaluation, a final interview with the Neuralink team), was accepted this past April as the trial’s 26th recipient and the first Canadian ALS patient to get the N1 implant. He recounts the May surgery in detail, including the robotic system that stitched 64 threads into his brain, and describes the app, Link, translating his neural signals into cursor control, which he was using within hours of waking up.
Marten walks through what daily use looks like, including weekly “brain training” exercises, a real-time neural-activity display, charging the implant via a beanie-mounted MagSafe charger, and using the implant for emailing, texting, social media, and gaming via a “Magic Box” that connects it to other devices. He also gives brief context on brain-computer interface history and quite candid about Musk, calling him “divisive” but saying he found him “easy to admire.
The piece closes on a heavier note, with Marten seeking to pursue medical assistance in dying as his symptoms progressed, noting that he’ll be able to communicate his final words to his family through Neuralink rather than facing a silent decline. He expresses hope the data from his case will help future ALS patients, even without a cure in his own lifetime.
Investor's Corner
Tesla Robotaxi gets a massive upgrade in Nevada
Nevada regulators just approved a massive expansion of Tesla’s robotaxi fleet across the entire county.
Tesla’s robotaxi footprint in Nevada just grew by roughly 500 times in a single regulatory vote.
The Nevada Transportation Authority approved Tesla’s full Autonomous Vehicle Network Company permit on Thursday, clearing the way for the company to deploy up to 5,000 driverless vehicles across Clark County over the next 12 months. The decision came during a four hour general session meeting that Tesla investor Sawyer Merritt watched live and reported on X, noting the vote replaces the interim order that had limited Tesla to just 10 robotaxis on a narrow stretch of the Las Vegas Strip.
EXCLUSIVE: Tesla has just officially received approval for its full Autonomous Vehicle Network Company permit in Nevada, clearing the way for Tesla to launch a paid public Robotaxi service in Las Vegas.
This officially allows @Tesla to deploy up to 5,000 robotaxis over the next… pic.twitter.com/DPs5UtUlrE
— Sawyer Merritt (@SawyerMerritt) August 20, 2026
That earlier cap, covered here after it surfaced on August 13, came with restrictions that looked stricter than what Tesla runs in Austin: a 45 mph speed ceiling, no airport pickups, and a geofence confined to the Strip corridor. The new approval extends Tesla’s operating authority to all of Clark County, with room to request an even wider geofence across the state.
Tesla representatives at the meeting said they have no intention of putting 5,000 cars on the road right away. Commercial rides are expected to start within 30 days, pending vehicle inspections, insurance filings, and fare approval, the standard steps every robotaxi operator in Nevada has had to clear.
Tesla’s own Robotaxi account replied to the news with a short line, The golden future is upon us.
The timing lines up with Tesla’s broader robotaxi push this month. The company is preparing to open Cybercab rides to the public in Austin as soon as this month, and it opened a sweepstakes for riders to win a seat at the launch event. Tesla filed its original application for a 5,000 vehicle Nevada fleet back in June, a request regulators trimmed to 10 vehicles when they issued the interim order in July. Thursday’s vote effectively grants the number Tesla asked for from the start.
Zoox, the Amazon owned robotaxi operator, has run in Nevada since 2025 and was capped at 100 vehicles before Thursday’s decision. Tesla’s new ceiling puts it well ahead of that comparison on paper, though the company has said its actual fleet size will depend on how quickly FSD v15 rolls out, the software update executives have called the gateway to scaling unsupervised robotaxi operations nationwide.